UY36795A - Procedimientos de purificacion de un virus producido in vitro y ensayo de eliminacion del virus - Google Patents

Procedimientos de purificacion de un virus producido in vitro y ensayo de eliminacion del virus

Info

Publication number
UY36795A
UY36795A UY0001036795A UY36795A UY36795A UY 36795 A UY36795 A UY 36795A UY 0001036795 A UY0001036795 A UY 0001036795A UY 36795 A UY36795 A UY 36795A UY 36795 A UY36795 A UY 36795A
Authority
UY
Uruguay
Prior art keywords
virus
purification procedures
produced
elimination test
procedure
Prior art date
Application number
UY0001036795A
Other languages
English (en)
Inventor
Buno Brett
Burdick Michael
Hotta Joann
Journigan Terri
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY36795A publication Critical patent/UY36795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/34—Organic compounds containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5768—Hepatitis A
    • C11D2111/10—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32511—Parechovirus, e.g. human parechovirus
    • C12N2770/32551—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En el presente documento se da a conocer un procedimiento para la purificación de un virus no envuelto o pseudoenvuelto producido in vitro que utiliza una composición con al menos un detergente. También se da a conocer un procedimiento para la purificación que puede utilizar múltiples detergentes y un procedimiento para la determinación de la presencia y/o el nivel de un virus no envuelto o pseudoenvuelto en una muestra.
UY0001036795A 2015-07-23 2016-07-15 Procedimientos de purificacion de un virus producido in vitro y ensayo de eliminacion del virus UY36795A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562196004P 2015-07-23 2015-07-23

Publications (1)

Publication Number Publication Date
UY36795A true UY36795A (es) 2016-09-30

Family

ID=56418394

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036795A UY36795A (es) 2015-07-23 2016-07-15 Procedimientos de purificacion de un virus producido in vitro y ensayo de eliminacion del virus

Country Status (21)

Country Link
US (1) US10336988B2 (es)
EP (1) EP3121268B1 (es)
JP (1) JP6734137B2 (es)
KR (1) KR102205026B1 (es)
CN (1) CN106367402B (es)
AR (1) AR105439A1 (es)
AU (1) AU2016206243B2 (es)
BR (1) BR102016016678A2 (es)
CA (1) CA2937089C (es)
ES (1) ES2712664T3 (es)
IL (1) IL246769B (es)
MX (1) MX2016009266A (es)
MY (1) MY179359A (es)
PL (1) PL3121268T3 (es)
PT (1) PT3121268T (es)
RU (1) RU2691026C1 (es)
SG (1) SG10201605869QA (es)
TR (1) TR201902201T4 (es)
TW (1) TW201704467A (es)
UY (1) UY36795A (es)
ZA (1) ZA201604895B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190092375A (ko) 2018-01-29 2019-08-07 그리폴스 다이어그노스틱 솔루션즈 인크. 임상 시료 내의 파보바이러스 b19를 균질화하기 위한 방법
KR20210079543A (ko) 2019-12-20 2021-06-30 삼성전자주식회사 고대역폭 메모리 및 이를 포함하는 시스템
JP2023141423A (ja) * 2022-03-24 2023-10-05 国立大学法人 東京大学 ウイルスの精製方法
CN115181816B (zh) * 2022-08-10 2023-01-06 杭州纽创生物检测有限公司 一种超低病毒滴度体系中病毒滴度的检测方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) * 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
CN101397335A (zh) * 1998-06-24 2009-04-01 基因创新有限公司 Hcv包膜蛋白颗粒:用于疫苗接种的用途
WO2003030624A2 (en) * 2001-10-12 2003-04-17 Chiron Corporation Hepatitis a virus nucleotide sequences, recombinant proteins and uses thereof
JPWO2006011580A1 (ja) 2004-07-27 2008-05-01 ジェノミディア株式会社 ウイルスエンベロープの精製方法
US7944468B2 (en) * 2005-07-05 2011-05-17 Northrop Grumman Systems Corporation Automated asymmetric threat detection using backward tracking and behavioral analysis
JP5034040B2 (ja) * 2006-07-13 2012-09-26 国立大学法人鳥取大学 肝炎の診断キット及び診断マーカー
WO2011116189A1 (en) * 2010-03-17 2011-09-22 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse

Also Published As

Publication number Publication date
PT3121268T (pt) 2019-02-26
JP2017023144A (ja) 2017-02-02
IL246769A0 (en) 2016-12-29
CN106367402A (zh) 2017-02-01
MX2016009266A (es) 2017-01-23
CA2937089A1 (en) 2017-01-23
US10336988B2 (en) 2019-07-02
BR102016016678A2 (pt) 2019-02-12
SG10201605869QA (en) 2017-02-27
AU2016206243B2 (en) 2021-04-01
US20170022480A1 (en) 2017-01-26
EP3121268B1 (en) 2018-12-26
CA2937089C (en) 2024-02-06
RU2691026C1 (ru) 2019-06-07
IL246769B (en) 2020-09-30
EP3121268A1 (en) 2017-01-25
AU2016206243A1 (en) 2017-02-09
JP6734137B2 (ja) 2020-08-05
CN106367402B (zh) 2022-03-08
KR20170012141A (ko) 2017-02-02
PL3121268T3 (pl) 2019-06-28
AR105439A1 (es) 2017-10-04
MY179359A (en) 2020-11-05
TR201902201T4 (tr) 2019-03-21
TW201704467A (zh) 2017-02-01
ES2712664T3 (es) 2019-05-14
KR102205026B1 (ko) 2021-01-19
ZA201604895B (en) 2021-04-28

Similar Documents

Publication Publication Date Title
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CL2017000111A1 (es) Moléculas con especificidad para cd45 y cd79
CL2016002772A1 (es) Composiciones de insulina de rápida acción
UY36759A (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
UY36795A (es) Procedimientos de purificacion de un virus producido in vitro y ensayo de eliminacion del virus
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CR20190471A (es) Moduladores de la expresión de pcsk9
BR112018071568A2 (pt) métodos, composições e usos relacionados aos mesmos
BR112016019588A2 (pt) produto de ativação de mmp-8, e, método de determinação da ativação da mmp-8 em uma amostra
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
ECSP20082339A (es) Moduladores de la expresión de apol1
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
MX2020003943A (es) Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
CL2021001246A1 (es) Moduladores de expresión irf5.
IT201700071789A1 (it) Apparato d’ispezione del fondo oculare
CU20170134A7 (es) 2-tiopirimidinonas
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos